Palisade Bio Announces Cancellation of Special Meeting of Stockholders
Palisade Bio (Nasdaq: PALI) announced on October 9, 2025 that it has cancelled its previously adjourned special meeting of stockholders that had been scheduled to reconvene on October 10, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Palisade Bio (Nasdaq: PALI) announced on October 9, 2025 that it has cancelled its previously adjourned special meeting of stockholders that had been scheduled to reconvene on October 10, 2025. The meeting was earlier reconvened on September 26, 2025 but adjourned without business due to a lack of quorum.
The company said it still has not received sufficient proxies to constitute a quorum and has withdrawn from stockholder consideration the proposals included in its definitive proxy statement filed with the SEC on August 18, 2025.
Positive
- None.
Negative
- Special meeting scheduled for Oct 10, 2025 cancelled
- Company withdrew proposals filed on Aug 18, 2025 from stockholder consideration
- Meeting reconvened on Sept 26, 2025 adjourned due to lack of quorum
Details
News Market Reaction – PALI
On Oct 10, the first trading day after this news, PALI closed 4.76% below the previous close.
Data tracked by StockTitan Argus for the Oct 10 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Carlsbad, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Company determined to cancel its previously adjourned special meeting of stockholders (the “Special Meeting”), which had been scheduled to reconvene on Friday, October 10, 2025, at 10:00 a.m. Pacific Time.
The Special Meeting was previously adjourned to, and reconvened on, September 26, 2025, but was adjourned again without any business being conducted, due to the lack of the required quorum as of the meeting time. As of today, the Company has still not received proxies that would constitute a quorum and has decided to cancel the Special Meeting and to withdraw from consideration by the Company’s stockholders the proposals set forth in the definitive proxy statement filed with the U.S. Securities and Exchange Commission on August 18, 2025.
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.